Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Bicara Therapeutics (NASDAQ:BCAX) reported Q2 2025 financial results and provided updates on its lead drug candidate ficerafusp alfa. The company highlighted strong Phase 1/1b trial results presented at ASCO 2025, showing a 54% confirmed objective response rate in HPV-negative head and neck cancer patients, with median duration of response of 21.7 months.
The company maintains a robust financial position with $436.6 million in cash, expected to fund operations into H1 2029. Q2 2025 saw increased R&D expenses of $24.8 million and a net loss of $27.4 million. The ongoing pivotal Phase 2/3 FORTIFI-HN01 trial continues enrollment, with additional Phase 1/1b expansion cohort data expected by Q1 2026.
Bicara Therapeutics (NASDAQ:BCAX) ha comunicato i risultati finanziari del secondo trimestre 2025 e ha fornito aggiornamenti sul suo principale candidato farmaco, ficerafusp alfa. L'azienda ha sottolineato i forti risultati della fase 1/1b presentati all'ASCO 2025, con un tasso di risposta obiettiva confermato del 54% nei pazienti con tumore della testa e del collo HPV-negativi e una durata mediana della risposta di 21,7 mesi.
L'azienda mantiene una solida posizione finanziaria con 436,6 milioni di dollari in cassa, importo ritenuto sufficiente a finanziare le operazioni fino alla prima met脿 del 2029. Nel Q2 2025 le spese R&S sono aumentate a 24,8 milioni di dollari e la perdita netta 猫 stata di 27,4 milioni di dollari. Il trial pivotale in corso, Phase 2/3 FORTIFI-HN01, continua l'arruolamento, con dati aggiuntivi della coorte di espansione della fase 1/1b attesi entro il primo trimestre 2026.
Bicara Therapeutics (NASDAQ:BCAX) inform贸 los resultados financieros del segundo trimestre de 2025 y ofreci贸 actualizaciones sobre su principal candidato a f谩rmaco, ficerafusp alfa. La compa帽铆a destac贸 los fuertes resultados de la fase 1/1b presentados en ASCO 2025, mostrando una tasa de respuesta objetiva confirmada del 54% en pacientes con c谩ncer de cabeza y cuello negativos para VPH, con una duraci贸n mediana de la respuesta de 21,7 meses.
La compa帽铆a mantiene una posici贸n financiera s贸lida con 436,6 millones de d贸lares en efectivo, suficientes para financiar las operaciones hasta la primera mitad de 2029. En el 2T 2025 aumentaron los gastos de I+D a 24,8 millones de d贸lares y la p茅rdida neta fue de 27,4 millones de d贸lares. El ensayo pivotal en curso, Phase 2/3 FORTIFI-HN01, sigue reclutando, y se esperan datos adicionales de la cohorte de expansi贸n de la fase 1/1b para el primer trimestre de 2026.
Bicara Therapeutics (NASDAQ:BCAX)電� 2025雲� 2攵勱赴 鞛鞁れ爜鞚� 氚滍憸頃橁碃 欤检殧 頉勲炒鞎诫 頂检劯霛柬懜鞀れ晫韺�(ficerafusp alfa)鞐� 雽�頃� 鞐呺嵃鞚错姼毳� 鞝滉车頄堨姷雼堧嫟. 須岇偓電� ASCO 2025鞐愳劀 氚滍憸頃� 臧曤牓頃� 1/1b靸� 瓴瓣臣毳� 臧曥“頄堨溂氅�, HPV 鞚岇劚 霊愱步攵�鞎� 頇橃瀽鞐愳劀 頇曥澑霅� 臧濌磤鞝� 氚橃潙毳犾澊 54%鞓�瓿� 氚橃潙鞚� 欷戩暀 歆�靻嶊赴臧勳潃 21.7臧滌洈鞚措澕瓿� 氚濏様鞀惦媹雼�.
須岇偓電� 4鞏�3660毵� 雼煬($436.6 million)鞚� 順勱笀鞚� 氤挫湢頃� 2029雲� 靸侂皹旮瓣箤歆� 鞖挫榿 鞛愱笀鞚� 臁半嫭頃� 瓴冹溂搿� 鞓堨儊霅橂┌ 瓴碃頃� 鞛靸來儨毳� 鞙犾頃橁碃 鞛堨姷雼堧嫟. 2025雲� 2攵勱赴 鞐瓣惮臧滊皽牍勲姅 2480毵� 雼煬搿� 歃濌皜頄堦碃 靾滌啇鞁れ潃 2740毵� 雼煬鞓�鞀惦媹雼�. 歆勴枆 欷戩澑 欷戩稊鞝� Phase 2/3 FORTIFI-HN01 鞁滍棙鞚� 霌彪鞚� 瓿勳啀頃橁碃 鞛堨溂氅�, 1/1b靸� 頇曥灔 旖旐樃韸胳潣 於旉皜 雿办澊韯半姅 2026雲� 1攵勱赴旯岇 氚滍憸霅� 鞓堨爼鞛呺媹雼�.
Bicara Therapeutics (NASDAQ:BCAX) a publi茅 ses r茅sultats financiers du deuxi猫me trimestre 2025 et a donn茅 des nouvelles de son principal candidat-m茅dicament, ficerafusp alfa. La soci茅t茅 a mis en avant les forts r茅sultats de la phase 1/1b pr茅sent茅s 脿 l'ASCO 2025, montrant un taux de r茅ponse objective confirm茅 de 54 % chez des patients atteints de cancers de la t锚te et du cou HPV-n茅gatifs, avec une dur茅e m茅diane de r茅ponse de 21,7 mois.
La soci茅t茅 conserve une position financi猫re solide avec 436,6 millions de dollars de tr茅sorerie, cens茅s financer les op茅rations jusqu'au premier semestre 2029. Au T2 2025, les d茅penses de R&D ont augment茅 脿 24,8 millions de dollars et la perte nette s'est 茅lev茅e 脿 27,4 millions de dollars. L'essai pivotal en cours, Phase 2/3 FORTIFI-HN01, continue son recrutement, et des donn茅es suppl茅mentaires de la cohorte d'extension de la phase 1/1b sont attendues d'ici le premier trimestre 2026.
Bicara Therapeutics (NASDAQ:BCAX) meldete die Finanzergebnisse f眉r das zweite Quartal 2025 und gab Updates zu seinem f眉hrenden Wirkstoffkandidaten ficerafusp alfa. Das Unternehmen hob die starken Phase鈥�1/1b鈥慐rgebnisse hervor, die auf der ASCO 2025 pr盲sentiert wurden und eine best盲tigte objektive Ansprechrate von 54% bei HPV鈥憂egativen Kopf鈥憉nd鈥慔als鈥慘rebs鈥慞atienten zeigten, mit einer medianen Ansprechdauer von 21,7 Monaten.
Das Unternehmen verf眉gt 眉ber eine robuste Finanzlage mit 436,6 Millionen US鈥慏ollar an liquiden Mitteln, die voraussichtlich die Gesch盲ftst盲tigkeit bis in die erste H盲lfte 2029 finanzieren. Im Q2 2025 stiegen die F&E鈥慉ufwendungen auf 24,8 Millionen US鈥慏ollar und der Nettoverlust belief sich auf 27,4 Millionen US鈥慏ollar. Die laufende pivotale Phase 2/3 FORTIFI鈥慔N01鈥慡tudie setzt die Rekrutierung fort; zus盲tzliche Daten der Expansionskohorte der Phase 1/1b werden bis Q1 2026 erwartet.
- Strong cash position of $436.6M expected to fund operations into H1 2029
- 54% confirmed objective response rate in Phase 1/1b trial for HPV-negative HNSCC
- Impressive 21.7-month median duration of response in trial responders
- 80% of responders achieved deep response with 鈮�80% tumor shrinkage
- 89% disease control rate in Phase 1/1b trial
- Increased net loss of $27.4M in Q2 2025, up from $17.0M in Q2 2024
- R&D expenses increased 57% to $24.8M compared to Q2 2024
- General and administrative expenses nearly doubled to $7.2M year-over-year
Insights
Bicara's ficerafusp alfa shows promising 54% response rate and 21.7-month duration in HPV-negative head and neck cancer with strong financials.
The updated Phase 1/1b data for ficerafusp alfa presents remarkably strong efficacy signals in HPV-negative head and neck cancer patients. The 54% confirmed objective response rate significantly exceeds historical benchmarks for standard-of-care therapies in this challenging population, where response rates typically hover around 20-25%. Most impressive is the median duration of response reaching 21.7 months - exceptionally long for this aggressive cancer type where responses often last only 4-6 months with existing treatments.
The 21.3-month median overall survival with a 46% 2-year survival rate demonstrates meaningful clinical benefit beyond tumor shrinkage. For context, current first-line standard-of-care typically yields median survival of 12-15 months in this population. The 80% deep response rate (鈮�80% tumor shrinkage) among responders suggests the dual-targeting mechanism effectively overcomes the immunosuppressive tumor microenvironment that has historically limited treatment efficacy.
The trial expansion into multiple dosing regimens (750mg weekly, 2000mg biweekly) and a CPS 0 cohort represents strategic clinical development - targeting dose optimization while exploring efficacy in the most treatment-resistant subgroup (CPS 0). The progression to a pivotal Phase 2/3 trial indicates regulatory confidence in the existing dataset. The expansion into colorectal cancer suggests potential broader application of the EGFR/TGF-尾 targeting mechanism across tumor types characterized by stromal barriers.
Bicara's $437M cash position provides 4-year runway through key clinical milestones, strengthening investment thesis despite increasing R&D spend.
Bicara's financial position remains exceptionally strong with $436.6 million in cash, providing an extended runway into the first half of 2029 - nearly 4 years of operational funding. This represents uncommon financial stability for a clinical-stage biotech with a single lead asset, significantly de-risking the investment case. The cash burn rate of approximately $53 million for the first half of 2025 (calculated from the December 2024 position of $489.7M) indicates disciplined capital management despite scaling clinical operations.
The increase in R&D expenses to $24.8 million (up from $15.8M year-over-year) reflects appropriate investment scaling as ficerafusp alfa advances into pivotal Phase 2/3 testing. This 57% increase aligns with the expanded development program now supporting multiple dose regimens and additional cohorts. Similarly, the G&A expense increase to $7.2 million (from $3.9M) represents the operational infrastructure buildout necessary to support a maturing clinical program.
The net loss of $27.4 million for Q2 remains manageable relative to the cash position, with approximately 16 quarters of funding at current burn rates. This financial buffer provides considerable flexibility to pursue the comprehensive clinical development strategy outlined, including multiple readouts through 2026, without near-term financing pressure. This extended runway through multiple value-creating clinical milestones significantly enhances Bicara's negotiating position for potential partnerships or future capital raises.
Updated data from Phase 1/1b trial presented at 2025 ASCO Annual Meeting demonstrated deep and durable responses in 1L HPV-negative R/M HNSCC
Data from additional Phase 1/1b expansion cohorts evaluating alternate dose regimens in HPV-negative patients expected by Q1 2026
Strong financial position with approximately
BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced financial results for the second quarter ended June 30, 2025 and provided a business update.
鈥淲e continue to make excellent progress with the development of ficerafusp alfa,鈥� said Claire Mazumdar, PhD, MBA, Chief Executive Officer of Bicara Therapeutics. 鈥淯pdated Phase 1/1b data recently presented at ASCO 2025 from the 1500mg weekly cohort underscore the differentiated ability of ficerafusp alfa to remodel the tumor stroma and drive tumor penetration, with deep, durable anti-tumor responses observed in HPV-negative recurrent/metastatic head and neck squamous cell carcinoma patients. These data provide a strong foundation for the continued advancement of our pivotal Phase 2/3 FORTIFI-HN01 trial, and reinforce our confidence in the study design. We also look forward to presenting data from two additional Phase 1/1b expansion cohorts evaluating alternate dose regimens in patients with HPV-negative disease, which are expected to further characterize the safety and efficacy profile of ficerafusp alfa in this population with high unmet need.鈥�
Pipeline Highlights
Bicara is developing ficerafusp alfa, a first-in-class, dual-action bifunctional epidermal growth factor receptor (EGFR)/transforming growth factor beta (TGF-尾) antibody designed to enhance tumor penetration by breaking barriers in the tumor microenvironment that have challenged the treatment of multiple solid tumor cancers.
FORTIFI-HN01: Pivotal Phase 2/3 Clinical Trial in 1L R/M HNSCC
Enrollment is ongoing in FORTIFI-HN01, a global, randomized, double-blind, placebo-controlled, pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab in first line (1L) recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), excluding patients with oropharyngeal squamous cell carcinoma associated with human papillomavirus infection (HPV-positive).
Phase 1/1b Clinical Trial in 1L R/M HNSCC
- Updated data with extended follow-up from a Phase 1/1b trial evaluating 1500mg ficerafusp alfa weekly in patients with 1L R/M HNSCC was highlighted in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
- In the efficacy evaluable human papillomavirus (HPV)-negative population (n=28):
- Median duration of response (DOR) of 21.7 months amongst responders (n=15).
- Median overall survival (OS) of 21.3 months; 2-year OS rate of
46% . 54% (15/28) confirmed objective response rate (ORR);64% (18/28) ORR, including three additional unconfirmed responses and21% (6/28) complete response rate.80% (12/15) of responders achieved a deep response (鈮�80% tumor shrinkage).- Disease control rate of
89% (25/28 patients). - Median progression-free survival of 9.9 months.
- Manageable safety profile consistent with previously reported adverse events.
- In the efficacy evaluable human papillomavirus (HPV)-negative population (n=28):
- Additional Phase 1b expansion cohorts evaluating ficerafusp alfa in 1L R/M HNSCC remain ongoing:
- Data from a cohort evaluating 750mg of ficerafusp alfa weekly in combination with pembrolizumab in HPV-negative patients are expected to be presented at a medical meeting in the fourth quarter of 2025 or the first quarter of 2026.
- Data from a cohort evaluating 2000mg of ficerafusp alfa every other week in combination with pembrolizumab in HPV-negative patients are expected to be presented at a medical meeting in the first quarter of 2026.
- A cohort evaluating 1500mg weekly of ficerafusp alfa in combination with pembrolizumab in HPV-negative patients with combined positive scores (CPS) of 0 continues to enroll. Data from this cohort are expected to be presented at a medical meeting in 2026.
Development of Ficerafusp Alfa Across Other Solid Tumor Types
- A Phase 1b expansion cohort evaluating ficerafusp alfa both as monotherapy and in combination with pembrolizumab in patients with 3L+ metastatic colorectal cancer (RAS/B-Rapidly Accelerated Fibrosarcoma (BRAF) wild type) is enrolling.
听Second Quarter 2025 Financial Results
- Cash Position: As of June 30, 2025, Bicara had cash and cash equivalents of
$436.6 million , compared to$489.7 million as of December 31, 2024. Based on its current operating and development plans, the Company expects that its existing cash and cash equivalents will fund operations into the first half of 2029. - Research and Development Expenses: Research and development expenses were
$24.8 million for the second quarter of 2025 as compared to$15.8 million for the second quarter of 2024. The increase was primarily due to additional costs associated with the initiation of FORTIFI-HN01, a pivotal Phase 2/3 clinical trial, as well as the Company鈥檚 ongoing Phase 1/1b clinical trials to advance ficerafusp alfa and an increase in personnel costs. - General and Administrative Expenses: General and administrative expenses were
$7.2 million for the second quarter of 2025 as compared to$3.9 million for the second quarter of 2024. The increase was primarily due to additional personnel costs and professional fees to support advancement of our clinical trials and operations as a public company. - Net Loss: Net loss totaled
$27.4 million for the second quarter of 2025 as compared to$17.0 million for the second quarter of 2024.
About Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara鈥檚 lead program, ficerafusp alfa, is a first-in-class bifunctional antibody designed to drive tumor penetration by breaking barriers in the tumor microenvironment that have challenged the treatment of multiple solid tumor cancers. Specifically, ficerafusp alfa combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-尾). Through this targeted mechanism, ficerafusp alfa reverses the fibrotic and immune-excluded tumor microenvironment driven by TGF-尾 signaling to enable tumor penetration that drives deep and durable responses. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit听听or follow us on LinkedIn or X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as 鈥渕ay,鈥� 鈥渕ight,鈥� 鈥渨ill,鈥� 鈥渃ould,鈥� 鈥渨ould,鈥� 鈥渟hould,鈥� 鈥減lan,鈥� 鈥渁nticipate,鈥� 鈥渋ntend,鈥� 鈥渂elieve,鈥� 鈥渆xpect,鈥� 鈥渆stimate,鈥� 鈥渟eek,鈥� 鈥減redict,鈥� 鈥渇uture,鈥� 鈥減roject,鈥� 鈥減otential,鈥� 鈥渃ontinue,鈥� 鈥渢arget鈥� and similar words or expressions, or the negative thereof, are intended to identify forward-looking statements, although not all contain identifying words. Any statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, Bicara鈥檚 strategy, business plans and focus; express or implied statements regarding the clinical development of ficerafusp alfa, including enrollment, progress and anticipated data readouts of Bicara鈥檚 Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab and the additional ongoing expansion cohorts of Bicara鈥檚 Phase 1b trial of ficerafusp alfa; the expected therapeutic potential and clinical benefits of ficerafusp alfa, including potential efficacy, depth, durability and tolerability; Bicara鈥檚 expected operating expenses and capital expenditure requirements, including its cash runway into the first half of 2029; and participation at upcoming conferences and the timing of data readouts. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks and uncertainties that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to uncertainties inherent in the development of product candidates, including the conduct of research activities and the conduct of clinical trials; uncertainties as to the availability and timing of results and data from clinical trials; whether results from prior preclinical studies and clinical trials will be predictive of the results of subsequent preclinical studies and clinical trials; regulatory developments in the United States and foreign countries; whether Bicara鈥檚 cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Bicara鈥檚 filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2024, its upcoming Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 and any subsequent filings Bicara makes with the SEC. In addition, any forward-looking statements represent Bicara鈥檚 views only as of today and should not be relied upon as representing its views as of any subsequent date. Bicara explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Bicara intends to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Company鈥檚 Investor Relations website, in addition to following the Company鈥檚 press releases, SEC filings, public conference calls, presentations, and webcasts.
| 听 | 听 | 听 | 听 | ||||||||||||
| BICARA THERAPEUTICS INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited, in thousands except shares and per share data) | |||||||||||||||
| 听 | 听 | 听 | 听 | ||||||||||||
| 听 | Three Months Ended June 30, | 听 | Six Months Ended June 30, | ||||||||||||
| 听 | 2025 | 听 | 2024 | 听 | 2025 | 听 | 2024 | ||||||||
| Operating expenses | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Research and development - related party | $ | 2,932 | 听 | 听 | $ | 1,510 | 听 | 听 | $ | 9,507 | 听 | 听 | $ | 5,091 | 听 |
| Research and development | 听 | 21,866 | 听 | 听 | 听 | 14,331 | 听 | 听 | 听 | 49,624 | 听 | 听 | 听 | 22,782 | 听 |
| General and administrative | 听 | 7,220 | 听 | 听 | 听 | 3,909 | 听 | 听 | 听 | 14,675 | 听 | 听 | 听 | 7,251 | 听 |
| Total operating expenses1 | 听 | 32,018 | 听 | 听 | 听 | 19,750 | 听 | 听 | 听 | 73,806 | 听 | 听 | 听 | 35,124 | 听 |
| Loss from operations | 听 | (32,018 | ) | 听 | 听 | (19,750 | ) | 听 | 听 | (73,806 | ) | 听 | 听 | (35,124 | ) |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Other income | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Interest income | 听 | 4,682 | 听 | 听 | 听 | 2,701 | 听 | 听 | 听 | 9,696 | 听 | 听 | 听 | 5,568 | 听 |
| Total other income | 听 | 4,682 | 听 | 听 | 听 | 2,701 | 听 | 听 | 听 | 9,696 | 听 | 听 | 听 | 5,568 | 听 |
| Net loss before income taxes | 听 | (27,336 | ) | 听 | 听 | (17,049 | ) | 听 | 听 | (64,110 | ) | 听 | 听 | (29,556 | ) |
| Income tax expense | 听 | (52 | ) | 听 | 听 | 鈥� | 听 | 听 | 听 | (124 | ) | 听 | 听 | (1 | ) |
| Net loss | $ | (27,388 | ) | 听 | $ | (17,049 | ) | 听 | $ | (64,234 | ) | 听 | $ | (29,557 | ) |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Net Loss per share, basic and diluted | $ | (0.50 | ) | 听 | $ | (19.01 | ) | 听 | $ | (1.18 | ) | 听 | $ | (38.19 | ) |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Weighted-average number common shares outstanding, basic and diluted | 听 | 54,539,230 | 听 | 听 | 听 | 896,744 | 听 | 听 | 听 | 54,496,862 | 听 | 听 | 听 | 774,012 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| 1 Expenses include the following non-cash stock-based compensation expense | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Research & Development | $ | 1,159 | 听 | 听 | $ | 251 | 听 | 听 | $ | 2,300 | 听 | 听 | $ | 481 | 听 |
| General and administrative | 听 | 2,333 | 听 | 听 | 听 | 787 | 听 | 听 | 听 | 4,643 | 听 | 听 | 听 | 1,704 | 听 |
| Total stock-based compensation expense | $ | 3,492 | 听 | 听 | $ | 1,038 | 听 | 听 | $ | 6,943 | 听 | 听 | $ | 2,185 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| BICARA THERAPEUTICS INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited, in thousands) | |||||||
| 听 | 听 | 听 | 听 | ||||
| 听 | June 30, 2025 | 听 | December 31, 2024 | ||||
| Assets | 听 | 听 | 听 | ||||
| Current assets: | 听 | 听 | 听 | ||||
| Cash and cash equivalents | $ | 436,606 | 听 | 听 | $ | 489,711 | 听 |
| Prepaid expenses and other assets | 听 | 7,785 | 听 | 听 | 听 | 12,822 | 听 |
| Total current assets | 听 | 444,391 | 听 | 听 | 听 | 502,533 | 听 |
| 听 | 听 | 听 | 听 | ||||
| Property and equipment, net | 听 | 117 | 听 | 听 | 听 | 155 | 听 |
| Right of use asset 鈥� operating lease | 听 | 2,237 | 听 | 听 | 听 | 690 | 听 |
| Other assets | 听 | 6,842 | 听 | 听 | 听 | 6,618 | 听 |
| Total assets | $ | 453,587 | 听 | 听 | $ | 509,996 | 听 |
| 听 | 听 | 听 | 听 | ||||
| Liabilities and stockholders鈥� equity | 听 | 听 | 听 | ||||
| Current liabilities: | 听 | 听 | 听 | ||||
| Accounts payable | $ | 2,041 | 听 | 听 | $ | 3,893 | 听 |
| Accounts payable 鈥� related party | 听 | 870 | 听 | 听 | 听 | 615 | 听 |
| Accrued expenses and other current liabilities | 听 | 12,000 | 听 | 听 | 听 | 12,875 | 听 |
| Accrued expenses and other current liabilities 鈥� related party | 听 | 1,242 | 听 | 听 | 听 | 鈥� | 听 |
| Operating lease liability 鈥� current portion | 听 | 1,074 | 听 | 听 | 听 | 607 | 听 |
| Total current liabilities | 听 | 17,227 | 听 | 听 | 听 | 17,990 | 听 |
| 听 | 听 | 听 | 听 | ||||
| Operating lease liability 鈥� net of current portion | 听 | 1,164 | 听 | 听 | 听 | 131 | 听 |
| Total liabilities | 听 | 18,391 | 听 | 听 | 听 | 18,121 | 听 |
| Total stockholders' equity | 听 | 435,196 | 听 | 听 | 听 | 491,875 | 听 |
| Total liabilities and stockholders鈥� equity | $ | 453,587 | 听 | 听 | $ | 509,996 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
Contacts
Investors
Rachel Frank
Media
Amanda Lazaro
1AB
FAQ
What were the key Phase 1/1b trial results for Bicara's (BCAX) ficerafusp alfa in head and neck cancer?
How much cash does Bicara Therapeutics (BCAX) have and how long will it last?
What is ficerafusp alfa and how does it work?
When will Bicara (BCAX) report additional clinical trial data?
What was Bicara Therapeutics' (BCAX) net loss in Q2 2025?
